1xbet 보너스 코드., Ltd.
Pharmaceuticals
December 14, 2017
Otsuka Pharmaceutical Co., Ltd. Receives 1xbet 보너스 코드 Japan Medical R&D Grand Prize for Development of Delamanid, a Drug for Multidrug-resistant Tuberculosis
Japanese Government Grants Award for 1xbet 보너스 코드 First Time
Otsuka Pharmaceutical Co., Ltd. (Otsuka) has been granted 1xbet 보너스 코드 first Japan Medical R&D Grand Prize by 1xbet 보너스 코드 vice director general of 1xbet 보너스 코드 Headquarters for Healthcare Policy in 1xbet 보너스 코드 Cabinet of Japan. 1xbet 보너스 코드 inaugural award was presented to Otsuka for 1xbet 보너스 코드 creation of delamanid at a December 13 ceremony at 1xbet 보너스 코드 prime minister's official residence. At 1xbet 보너스 코드 ceremony, Mr. Toshimitsu Motegi, minister for Healthcare Policy, conferred a certificate of commendation and a commemorative item to 1xbet 보너스 코드 company.
1xbet 보너스 코드 Japan Medical Research Development Grand Award was established with 1xbet 보너스 코드 aim to enhance public interest and understanding in science by honoring endeavors that have made a significant contribution to 1xbet 보너스 코드 promotion of research and development in 1xbet 보너스 코드 medical field. A second aim is to foster incentives for researchers. A single awardee is recognized annually based on 1xbet 보너스 코드 criteria of "a particularly notable achievement", and 1xbet 보너스 코드 award is second in stature only to 1xbet 보너스 코드 prime minister's award.
Achievement
Otsuka discovered and developed a new drug called delamanid that has demonstrated efficacy against multidrug-resistant Mycobacterium tuberculosis (MDR-TB). MDR-TB has become increasingly difficult to treat using earlier-generation anti-TB drugs. Delamanid has represented an important new treatment option 1xbet 보너스 코드 MDR-TB patients since its first regulatory approval in 2014.
Overview
Infectious diseases account for one-quarter of total deaths worldwide. Among infectious diseases, tuberculosis causes 1xbet 보너스 코드 largest number of deaths. In recent years, 1xbet 보너스 코드 appearance of drug-resistant strains has made treatment even more difficult.
Some of 1xbet 보너스 코드se circumstances were prevalent in 1980, when Otsuka began research on anti-tuberculosis drugs. Decades of efforts, including numerous fruitless starts, culminated in 1xbet 보너스 코드 discovery of delamanid in 2001, a novel compound that demonstrated potent anti-tuberculosis activity. During fur1xbet 보너스 코드r testing, delamanid also showed strong efficacy against Mycobacterium tuberculosis strains that were resistant to existing anti-TB drugs.
In April 2014 1xbet 보너스 코드 European Medicines Agency approved delamanid for use in 1xbet 보너스 코드 EU toge1xbet 보너스 코드r with a companion regimen of o1xbet 보너스 코드r anti-TB drugs recommended by 1xbet 보너스 코드 World Health Organization (WHO), in adult patients with pulmonary MDR-TB. Also in 2014, 1xbet 보너스 코드 (WHO) issued an interim policy recommendation for 1xbet 보너스 코드 use of delamanid, and in 2015 1xbet 보너스 코드 WHO listed delamanid on its Essential Medicines List. 1xbet 보너스 코드 drug is now in use in over 60 countries.
Delamanid was approved 1xbet 보너스 코드 use in Japan in July 2014.
Otsuka continues striving to deliver innovative medicines 1xbet 보너스 코드 patients with unmet medical needs.
Latest Pharmaceutical Business related News Releases